Article info

Download PDFPDF

794 TKM-011, Anti-CD20 antibody confers multi-properties against burkitt’s lymphoma in comparable efficacy to rituximab and obinutuzumab
Free

Authors

Citation

Panaampon J, Okada S
794 TKM-011, Anti-CD20 antibody confers multi-properties against burkitt’s lymphoma in comparable efficacy to rituximab and obinutuzumab

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.